108655-56-7

Basic information

• Product Name: Carbamic acid, (3-amino-2-pyridinyl)-, 1,1-dimethylethyl ester (9CI)
• Synonyms: Carbamic acid, (3-amino-2-pyridinyl)-, 1,1-dimethylethyl ester (9CI);tert-Butyl (3-aMinopyridin-2-yl)carbaMate;Tert-Butyl (3-Aminopyridin-2-Yl)Carbamate(WX606110)
• CAS NO: 108655-56-7
• Molecular Formula: C₁₀H₁₅N₃O₂
• Molecular Weight: 209.245
• Product Categories: N-BOC
• Mol File: 108655-56-7.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 313.8±27.0 °C(Predicted)
• Appearance: /
• Density: 1.202±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 12.16±0.70(Predicted)
• CAS DataBase Reference: Carbamic acid, (3-amino-2-pyridinyl)-, 1,1-dimethylethyl ester (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Carbamic acid, (3-amino-2-pyridinyl)-, 1,1-dimethylethyl ester (9CI)(108655-56-7)
• EPA Substance Registry System: Carbamic acid, (3-amino-2-pyridinyl)-, 1,1-dimethylethyl ester (9CI)(108655-56-7)

Safety Data

• Hazardous Substances Data: 108655-56-7(Hazardous Substances Data)

Usage

General Description

Carbamic acid, (3-amino-2-pyridinyl)-, 1,1-dimethylethyl ester (9CI) is an organic compound with the molecular formula C9H14N2O2. It is also known as tert-butyl 3-aminopyridine-2-carbamate and is commonly used as an intermediate in the synthesis of pharmaceutical drugs. Carbamic acid, (3-amino-2-pyridinyl)-, 1,1-dimethylethyl ester (9CI) is a tert-butyl ester derivative of carbamic acid and contains a 3-amino-2-pyridinyl group, which gives it potential pharmacological properties. It is often used in the research and development of new pharmaceuticals and agrochemicals. However, it is important to handle this chemical with care due to its potential hazards and toxicity.

Upstream product

• 1040363-53-8 tert-butyl 3-nitropyridin-2-ylcarbamate 
• 99314-91-7 N²,N³-dibenzyloxycarbonyl-2,3-diaminopyridine 
• 75-65-0 tert-butyl alcohol 

Relevant articles and documents

Synthesis and evaluation of novel GSK-3β inhibitors as multifunctional agents against Alzheimer's disease

To target the multi-facets of Alzheimer's disease (AD), a series of novel GSK-3β inhibitors containing the 2,3-diaminopyridine moiety were designed and synthesized. The amide derivatives 5a-f showed moderate potency against GSK-3β with weak Cu2+, Zn2+ and Al3+ chelating ability. The imine derivatives 9a, 9b and 9e were potent GSK-3β inhibitors and selective Cu2+and Al3+ chelators. The 1,2-diamine derivatives 10a-e were strong metal-chelators, but decreased or lost their GSK-3β inhibitory potency. In vitro, compounds 9a, 9b and 9e, especially 9b, exhibited good Cu2+-induced Aβ aggregation inhibition, Cu2+-Aβ complex disaggregation, ROS formation inhibition, and antioxidant activities. In cells, compounds 9a, 9b and 9e can inhibit tau protein phosphorylation and protect neuro cells against Cu2+-Aβ1–42 and H2O2-induced cell damage. Furthermore, compound 9b was predicted to have the ability to pass the BBB with drug likeness properties. Therefore, compound 9b might be a good lead for the development of novel GSK-3β inhibitors targeting multi-facets of AD.

HETEROCYCLIC-SUBSTITUTED PIPERDINE COMPOUNDS AND THE USES THEREOF

The invention relates to Heterocyclic-Substituted Piperidine Compounds, compositions comprising an effective amount of a Heterocyclic-Substituted Piperidine Compound and methods to treat or prevent a condition, such as pain, comprising administering to an animal in need thereof an effective amount of a Heterocyclic-Substituted Piperidine Compound